A Novel Hydrophilic Interaction Chromatography Assay Characterization of 4-Pyridoxic Acid, an Emergent Renal Organic Anion Transporter 1/3 Transporter Biomarker

References

• Fowler S , MorcosPN, ClearyYet al. Progress in prediction and interpretation of clinically relevant metabolic drug–drug interactions: a minireview illustrating recent developments and current opportunities. Curr. Pharmacol. Rep.3(1), 36–49 (2017).
   PubMedGoogle Scholar
• Kumar S , SharmaR, RoychowdhuryA. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective. Curr. Med. Chem.19(21), 3605–3621 (2012).
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK , MeyersonG, HagbjorkAL, JuricS, TereliusY. A strategy for early-risk predictions of clinical drug–drug interactions involving the GastroPlus(TM) DDI module for time-dependent CYP inhibitors. Xenobiotica48(4), 348–356 (2018).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan J , YoshidaK, AryaV, ZhangL. Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1. J. Clin. Pharmacol.56(Suppl. 7), S59–S72 (2016).
   PubMedGoogle Scholar
• Rodrigues AD , TaskarKS, KusuharaH, SugiyamaY. Endogenous probes for drug transporters: balancing vision with reality. Clin. Pharmacol. Ther.103(3), 434–448 (2018).
   PubMed Web of Science ®Google Scholar
• Ito S , KusuharaH, KumagaiYet al. N-methylnicotinamide is an endogenous probe for evaluation of drug–drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). Clin. Pharmacol. Ther.92(5), 635–641 (2012).
   PubMed Web of Science ®Google Scholar
• Luo L , KayJ, ZhangJet al. LCMS/MS assay for N(1)-methylnicotinamide in humans, an endogenous probe for renal transporters. Bioanalysis10(9), 673–689 (2018).
   PubMed Web of Science ®Google Scholar
• Bednarczyk D , BoiselleC. Orga–nic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III. Xenobiotica46(5), 457–466 (2016).
   PubMed Web of Science ®Google Scholar
• Lai Y , MandlekarS, ShenHet al. Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug–drug interactions mediated by organic anion transporting polypeptide inhibition. J. Pharmacol. Exp. Ther.358(3), 397–404 (2016).
   PubMed Web of Science ®Google Scholar
• King-Ahmad A , ClemensS, RamanathanRet al. A fully automated and validated human plasma LC–MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III. Bioanalysis10(9), 691–701 (2018).
   PubMed Web of Science ®Google Scholar
• Kindla J , FrommMF, KonigJ. In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions. Expert Opin. Drug Metab. Toxicol.5(5), 489–500 (2009).
   PubMed Web of Science ®Google Scholar
• Shen H , ChenW, DrexlerDMet al. Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects. Drug Metab. Dispos.45(8), 908–919 (2017).
   PubMed Web of Science ®Google Scholar
• Minato K , SuzukiM, NagaoH, SuzukiR, OchiaiH. Development of analytical method for simultaneous determination of five rodent unique bile acids in rat plasma using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.1002, 399–410 (2015).
   PubMed Web of Science ®Google Scholar
• Rago B , TierneyB, RodriguesAD, LHC, RamanathanR. A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers. Bioanalysis10(9), 645–657 (2018).
   PubMed Web of Science ®Google Scholar
• McChrisley B , ThyeFW, McNairHM, DriskellJA. Plasma B6 vitamer and 4-pyridoxic acid concentrations of men fed controlled diets. J. Chromatogr.428(1), 35–42 (1988).
   PubMed Web of Science ®Google Scholar
• Shen H , NelsonDM, OliveiraRVet al. Discovery and validation of pyridoxic acid and homovanillic acid as novel endogenous plasma biomarkers of organic anion transporter (OAT) 1 and OAT3 in cynomolgus monkeys. Drug Metab. Dispos.46(2), 178–188 (2018).
   PubMed Web of Science ®Google Scholar
• Shen H , HolenarsipurVK, MariappanTTet al. Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects. J. Pharmacol. Exp. Ther.368(1), 136–145 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang X , TangX, DalyTM. A one-step NIST traceable HPLC method for quantitation of vitamin B6 and 4-pyridoxic acid in human plasma. Pract. Lab. Med.21, e00160 (2020).
   PubMedGoogle Scholar
• Cabo R , KozikK, MilanowskiMet al. A simple high-performance liquid chromatography (HPLC) method for the measurement of pyridoxal-5-phosphate and 4-pyridoxic acid in human plasma. Clin. Chim. Acta433, 150–156 (2014).
   PubMed Web of Science ®Google Scholar
• Lee JW , WeinerRS, SailstadJMet al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res.22(4), 499–511 (2005).
   PubMed Web of Science ®Google Scholar
• Hougton R , GoutyD, AllinsonJet al. Recommendations on biomarker bioanalytical method validation by GCC. Bioanalysis4(20), 2439–2446 (2012).
   PubMed Web of Science ®Google Scholar
• Yang E , WelinkJ, CapeSet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (part 1 - small molecules, peptides and small molecule biomarkers by LC–MS). Bioanalysis8(22), 2363–2378 (2016).
   PubMed Web of Science ®Google Scholar
• Jones BR , SchultzGA, EcksteinJA, AckermannBL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis4(19), 2343–2356 (2012).
   PubMed Web of Science ®Google Scholar
• Ahmad A , OgungbenroK, KunzeAet al. Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters. CPT Pharmacometrics Syst. Pharmacol.10(5), 467–477 (2021).
   PubMedGoogle Scholar